AR011957A1 - Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal - Google Patents

Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal

Info

Publication number
AR011957A1
AR011957A1 ARP980101061A ARP980101061A AR011957A1 AR 011957 A1 AR011957 A1 AR 011957A1 AR P980101061 A ARP980101061 A AR P980101061A AR P980101061 A ARP980101061 A AR P980101061A AR 011957 A1 AR011957 A1 AR 011957A1
Authority
AR
Argentina
Prior art keywords
dolastatin
cyclical
hetero
functionalities
carbonyl
Prior art date
Application number
ARP980101061A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of AR011957A1 publication Critical patent/AR011957A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1027Tetrapeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se relaciona con nuevos péptidos que son de utilidad como agentes anticancerígenos. Los compuestos de la invencion presentan laformula (I): A - B - D - E - F - G, donde A, B, D y E son residuos de de alfa-aminoácidos.En una realizacion, F es un residuo del ácidoazacicloalcancarboxílico. En esta realizacion, G es un radical monovalente, por ejemlo, un átomo de hidrogeno, un grupo alquilo, un grupo arilo o un grupoheteroarilo. en otra realizacion, F es un grupo azacicloalquilo y G es un grupo heteroarilo conectado a F mediante un enlace carbono-carbono. En otrarealizacion, la invencion incluye un método para tratar el cáncer en un mamífero, como un ser humano, que comprende la administraciona dichomamífero de una cantidad efectiva de un compuesto de formula (I) en una composicion aceptable para uso farmacéutico.
ARP980101061A 1997-03-10 1998-03-10 Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal AR011957A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/814,577 US5965537A (en) 1997-03-10 1997-03-10 Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus

Publications (1)

Publication Number Publication Date
AR011957A1 true AR011957A1 (es) 2000-09-13

Family

ID=25215470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101061A AR011957A1 (es) 1997-03-10 1998-03-10 Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal

Country Status (17)

Country Link
US (1) US5965537A (es)
EP (1) EP0981539A1 (es)
JP (1) JP2001518084A (es)
KR (1) KR20000076099A (es)
CN (1) CN1252806A (es)
AR (1) AR011957A1 (es)
AU (1) AU744511B2 (es)
BR (1) BR9808017A (es)
CA (1) CA2297164A1 (es)
CO (1) CO4950525A1 (es)
HR (1) HRP980124A2 (es)
HU (1) HUP0001758A3 (es)
IL (1) IL131596A0 (es)
NO (1) NO994364L (es)
TW (1) TW505657B (es)
WO (1) WO1998040400A1 (es)
ZA (1) ZA981957B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CN101307046B (zh) 2000-10-30 2012-08-15 詹森药业有限公司 三肽酶抑制剂
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
PT1545613E (pt) * 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc IAP BIR DOMAIN BINDING COMPOUNDS
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
US9987255B2 (en) 2014-12-19 2018-06-05 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
CN104952808A (zh) * 2015-06-12 2015-09-30 广州先艺电子科技有限公司 一种预置金锡盖板及其制造方法
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
CN109776342A (zh) * 2019-02-26 2019-05-21 北京大学深圳研究生院 顺式β-氨基酸及其衍生物的合成方法
US20240132487A1 (en) * 2019-10-17 2024-04-25 Givaudan Sa Substituted azacyles as trmp8 modulators
JPWO2023033129A1 (es) 2021-09-03 2023-03-09

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US5091368A (en) * 1990-08-08 1992-02-25 Harbor Branch Oceanographic Institution, Inc. Biologically active compounds from blue-green algae
EP0598129B1 (en) * 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
AU679479B2 (en) * 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof

Also Published As

Publication number Publication date
TW505657B (en) 2002-10-11
BR9808017A (pt) 2000-03-08
NO994364D0 (no) 1999-09-09
AU744511B2 (en) 2002-02-28
AU6448298A (en) 1998-09-29
ZA981957B (en) 1999-09-09
HRP980124A2 (en) 1998-12-31
HUP0001758A2 (hu) 2001-05-28
CN1252806A (zh) 2000-05-10
CA2297164A1 (en) 1998-09-17
NO994364L (no) 1999-11-09
HUP0001758A3 (en) 2001-12-28
IL131596A0 (en) 2001-01-28
JP2001518084A (ja) 2001-10-09
US5965537A (en) 1999-10-12
CO4950525A1 (es) 2000-09-01
WO1998040400A1 (en) 1998-09-17
KR20000076099A (ko) 2000-12-26
EP0981539A1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
AR011957A1 (es) Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR018501A1 (es) Derivados de la dolastatina 15
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2038613T3 (es) Procedimiento para preparar derivados de 4,5,6,7-tetrahidro-1h-imidazo(4,5-c)piridina y analogos de los mismos que tienen actividad antihipertensiva.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
PT973801E (pt) Antagonistas de gnrh
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
BR0208017A (pt) Combinação compreendendo combretastatina e agentes anticâncer
FI892005A (fi) Molekulaera beten och ett foerfarande foer deras anvaendning.
AR015434A1 (es) Derivados de eritromicina con puente en 6,9, procedimientos para su preparacion, composicion farmaceutica para tratar infecciones bacterianas que los contiene y su uso para la manufactura de un medicamento
ES554784A0 (es) Un metodo para preparar peptidos que inhiben la liberacion de gonadotropina por la glandula pituitaria en mamiferos
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos
ES2088661T3 (es) Bis-naftalimidas fuertemente solubles en agua utiles como agentes anti-cancerigenos.
AR031126A1 (es) Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
ES2134798T3 (es) Uso de analogos de somatostatina para el tratamiento de melanomas.